

CELL THERAPEUTICS INC  
Form 8-K  
April 01, 2005

---

## **SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

### **FORM 8-K**

---

#### **CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report: (Date of earliest event reported): March 28, 2005**

---

## **CELL THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

---

**Washington**  
**(State or other jurisdiction of  
incorporation or organization)**

**001-12465**  
**(Commission File Number)**

**91-1533912**  
**(I.R.S. Employer  
Identification Number)**

**501 Elliott Avenue West, Suite 400**

**Seattle, Washington 98119**

**(Address of principal executive offices)**

Edgar Filing: CELL THERAPEUTICS INC - Form 8-K

**Registrant's telephone number, including area code: (206) 282-7100**

**Not applicable**

**(Former name or former address, if changed since last report).**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.**

On March 28, 2005, James Canfield resigned from his position as Chief Administrative Officer and Executive Vice President of Cell Therapeutics, Inc. (the Corporation ) effective as of April 1, 2005. The Corporation does not currently intend to appoint a new officer to this position.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CELL THERAPEUTICS, INC.

Date: April 1, 2005

By: /s/ Louis A. Bianco

---

Louis A. Bianco  
Executive Vice President, Finance and Administration

(Principal Accounting Officer)